CAESAREA, Israel, March 19, 2017 /PRNewswire/ --
Itamar Medical Ltd. (TASE: ITMR) wishes to clarify its recent press release, "An Important Recognition in the US Market for the WatchPAT™ Device" from March 16th.
Certain language in the press release mistakenly implies that the new AASM clinical practice guideline formally endorses Itamar Medical's WatchPAT™ product. In fact, the new AASM guideline was solely referring to the Peripheral Arterial Tonometry (PAT) technology as technically adequate based on evidence, and not to a specific product or device manufacturer.
Itamar Medical wishes to publicly and sincerely apologize for any potential misunderstanding and inconvenience this caused to the AASM, its members or their patients.
About Itamar Medical Ltd.
Itamar Medical Ltd. is a publicly traded medical device company (TASE:ITMR) that develops and markets innovative diagnostic and therapy solutions for sleep breathing disorders and cardiovascular conditions.
Chief Executive Officer and President
SOURCE Itamar Medical Ltd